<DOC>
	<DOCNO>NCT01816620</DOCNO>
	<brief_summary>The purpose prospective study determine efficacy safety lenalidomide plus dexamethasone patient newly diagnose POEMS syndrome .</brief_summary>
	<brief_title>Study Evaluate Lenalidomide Plus Dexamethasone Patients With Newly Diagnosed POEMS Syndrome</brief_title>
	<detailed_description>The investigator propose use adverse effect well need dose reduction criterion judge tolerability treatment . The primary endpoint would hematological response rate accord international myeloma work group ( IMWG ) response criterion amyloidosis neurological response rate define overall neuropathy limitation scale ( ONLS ) score . This study expect enroll approximately 41 subject .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>POEMS Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients must understand voluntarily sign informed consent form . 2 . Older 18 year old time sign consent . 3 . Meet diagnostic criterion POEM syndrome . 4 . Must cytotoxic treatment naive . However , previous exist corticosteroid ( prednisone dexamethasone ) intravenous immunoglobin ( IVIG ) therapy allow . 5 . Women childbearing potential must understand study medication could potential teratogenic risk . They undergo complete contraception study period . 6 . Male subject must agree use condom throughout study drug therapy . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant lactating female . 3 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1.0×10E9 cell/L . Platelet count &lt; 50×10E9 cell/L . Renal failure require dialysis . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time normal upper limit . 4 . Prior history malignancy , include basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix , carcinoma situ breast , T1a T1b prostate cancer . 5 . Known hypersensitivity prior history uncontrollable side effect dexamethasone therapy . 6 . Prior use cytotoxic drug . 7 . Subjects unable unwilling undergo antithrombotic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>POEMS Syndrome</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>plasma cell disorder</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>